E
Biofrontera Inc. BFRI
$0.799 -$0.001-0.13%
Recommendation
Sell
Prev Close
$0.813
Volume
23,142
Avg Vol (90D)
609,452
Market Cap
$7.21M
Dividend & Yield
--
52-Week Range
$0.6513 - $2.43
P/E (TTM)
--
EPS (TTM)
-$4.28
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Good
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
Biofrontera Inc. Reports Record Sales and Strategic Advances
3/25/2025 - TipRanks Financial Blog
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...
3/22/2025 - GuruFocus
Q4 2024 Biofrontera Inc Earnings Call Transcript
3/22/2025 - GuruFocus
Biofrontera Inc. Reports Record Revenue Growth in 2024
3/22/2025 - TipRanks Financial Blog
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript
3/21/2025 - SeekingAlpha
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript
3/21/2025 - Seeking Alpha: Transcripts
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
3/21/2025 - GuruFocus
Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year
3/21/2025 - The Fly
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
3/21/2025 - Globe Newswire
Biofrontera completes patient enrollment in Phase 3 study of Ameluz
3/18/2025 - The Fly
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
3/18/2025 - Globe Newswire
Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Drops By 50.6%
3/16/2025 - Ticker Report
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
3/11/2025 - GuruFocus
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
3/11/2025 - Globe Newswire
Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues
2/27/2025 - Simply Wall St
Rosalind Advisors, Inc. Expands Stake in Biofrontera Inc with Significant Share Acquisition
2/12/2025 - GuruFocus
Biofrontera Inc. files to sell 5.72M shares of common stock for holders
1/21/2025 - The Fly
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study
1/8/2025 - TipRanks Financial Blog
biofrontera inc announces achievement of key milestone in phase 3 study of ameluzphotodynamic therapy pdt in the treatment of superficial basal cell carcinoma sbcc
1/8/2025 - GuruFocus
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study
1/8/2025 - The Fly
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
1/8/2025 - Globe Newswire
Biofrontera announces 100 RhodoLED XL machines placed in U.S. market
12/23/2024 - The Fly
Biofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market
12/23/2024 - Globe Newswire
Biofrontera (NASDAQ:BFRI) vs. Amicus Therapeutics (NASDAQ:FOLD) Head to Head Analysis
12/16/2024 - Ticker Report
Income Statement
Total Revenue (TTM)
$37.32M
EBITDA (TTM)
-$16.79M
EBIT (TTM)
-$17.21M
Net Income (TTM)
-$17.76M
Balance Sheet
Total Assets (Q)
$22.10M
Total Debt (Q)
$4.92M
Total Liabilities (Q)
$17.67M
Book Value Per Share (Q)
$0.4996
Cash Flow
Cash from Operations (TTM)
-$10.27M
Cash from Investing (TTM)
-$3.00K
Cash from Financing (TTM)
$14.84M
Net Change in Cash (TTM)
$4.56M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.46
7-Day Total Return
-22.43%
30-Day Total Return
-32.29%
60-Day Total Return
-26.70%
90-Day Total Return
8.86%
Year to Date Total Return
-26.70%
1-Year Total Return
-58.39%
2-Year Total Return
-93.23%
3-Year Total Return
-98.81%
5-Year Total Return
--
52-week Low
Nov 18, 2024 - $0.6513
52-week High
Apr 10, 2024 - $2.43
Valuation
Market Cap
$7.21M - Nano Cap
Enterprise Value
$6.22M
Price/Sales (TTM)
0.16
Price/Book (Q)
1.63
Dividends and Shares
Shares Outstanding
7.57M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biofrontera-us.com
Phone Number
781 245 1325
Address
120 Presidential Way
Woburn, MA 01801
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings